AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-80403167/king-pharmaceuticals-submits-new.html" title="Facts and information about King Pharmaceuticals Submits New Drug Application For Theelin.(for the treatment of vaginal and vulvar atrophy)">King Pharmaceuticals Submits New Drug Application For Theelin.(for the treatment of vaginal and vulvar atrophy)</a>
Close
Set up an RSS feed that alerts you when new articles from Women's Health Weekly are available.
Frequently asked questions about RSS feeds
King Pharmaceuticals Submits New Drug Application For Theelin.(for the treatment of vaginal and vulvar atrophy)
2001 DEC 6 - (NewsRx.com & NewsRx.net) -- King Pharmaceuticals, Inc., (KG) has submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for Theelin (estrone injectable suspension, USP), an injectable estrogen replacement therapy for women. The indications sought are (1) treatment of moderate to severe vasomotor symptoms of menopause, and (2) treatment of vaginal and vulvar atrophy.
"We ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- The FDA has approved King Pharmaceuticals' new drug application for an Altace...
- Magazine article from: Medical Marketing & Media April 1, 2007 700+ words
The FDA has approved King Pharmaceuticals' new drug application for an Altace (ramipril) tablet formulation. King expects to be in a position to launch the new formulation sometime during the fourth quarter of 2007 or the first quarter of 2008.
- FDA clears King's Altace tablet NDA.(King Pharmaceuticals Inc.)(new drug...
- Newspaper article from: Pharma Marketletter March 5, 2007 700+ words
The US Food and Drug Administration has approved King Pharmaceuticals' New Drug Application for an Altace (ramipril) tablet formulation. King says it expects to be in a position to launch the new formulation sometime during the fourth quarter of 2007 or the first quarter of 2008.
- King Pharmaceuticals Submits New Drug Application for Theelin(R), an Injectable...
- Press release article from: PR Newswire October 31, 2001 700+ words
BRISTOL, Tenn., Oct. 31 /PRNewswire/ -- King Pharmaceuticals, Inc. (NYSE: KG) reported that the Company submitted today, Wednesday, October 31, 2001, a New Drug Application (NDA) with the U.S. Food and Drug Administration...
- King Pharmaceuticals Submits Supplemental New Drug Application for Altace(R).
- Press release article from: PR Newswire January 19, 2000 700+ words
...Tenn., Jan. 19 /PRNewswire/ -- King Pharmaceuticals, Inc. (Nasdaq: KING) announced...has submitted a supplemental new drug application to the U.S. Food and Drug Administration...s review of the supplemental new drug application, the high cost and uncertainty of...
- King Pharmaceuticals' Investigational New Drug Application for an Extended...
- Press release article from: PR Newswire February 3, 2004 700+ words
King Pharmaceuticals, Inc. announced today that...an important step forward for King Pharmaceuticals. The successful development...formulation of Sonata(R)." About King Pharmaceuticals King, headquartered in Bristol...
- King Pharmaceuticals Announces Submission of New Drug Application for...
- Press release article from: Business Wire December 18, 2008 700+ words
BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE: KG) today announced it has submitted a New Drug Application (NDA) for CorVue([TM]) (binodenoson) for injection to the U.S. Food and Drug Administration (FDA). CorVue([TM...
- FDA Accepts for Review New Drug Application for Estrasorb(TM), a Topical...
- Press release article from: PR Newswire September 5, 2001 700+ words
BRISTOL, Tenn., Sept. 5 /PRNewswire/ -- King Pharmaceuticals, Inc. (NYSE: KG) reported today that the U...Administration (FDA) has accepted for review the New Drug Application (NDA) for Estrasorb(TM) (17-beta- estradiol...
- King Pharmaceuticals, Inc.(Brief Article)
- Magazine article from: Medical Marketing & Media May 1, 2000 700+ words
King Pharmaceuticals, Inc.'s supplemental new drug application for Altace (ramipril), an angiotensin converting enzyme inhibitor, was accepted for review by the Food and Drug Administration.